New England Journal of Medicine · 2024 · 186 citations · 20 references
MedicineGeneticsHematologyCell TherapyGenome EditingStem Cell BiologyAnemiaHematopoietic Stem Cell BiologyRed Blood Cell DisordersRed Blood Cell TransfusionSickle Cell DiseaseTransfusion SupportBeta-thalassemia Gene TherapyCrispr-cas9 Ex Vivo EditingCrispr-cas9 Genome EditingGene Editing TherapyHematopoietic Stem Cell EditingHemoglobin Synthesis DefectsRed Blood Cell Transfusion SafetySickle Cell Disease Gene Editing
BACKGROUND: in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). METHODS: -like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. RESULTS: A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. CONCLUSIONS: Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678.).
20
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul, David Altshuler, Maria Domenica Cappellini et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text
Life Sciences, Genetics, Hematology +17
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Matthew C. Canver, Elenoe C. Smith, Falak Sher et al. · Nature · 2015 · 910 citations
Genetics in Medicine · 2010 · 652 citations · Full text
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Haydar Frangoul, Franco Locatelli, Akshay Sharma et al. · New England Journal of Medicine · 2024 · 380 citations
Life Sciences, Genetics, Hematology +17